DUSA Completes Enrollment For Phase IIb Trial Of Levulan(R) Photodynamic Therapy For Moderate To Severe Acne

DUSA Pharmaceuticals, Inc.(R) (NASDAQ GM:DUSA), is pleased to announce that the acne Phase IIb trial has achieved its goal of 260 participants, thus completing enrollment. The study’s objective is to determine and compare the safety and efficacy of multiple broad area photodynamic therapy (PDT) treatments with Levulan® Kerastick® in combination with BLU-U® brand blue light versus use of the BLU-U alone in patients with moderate to severe facial acne vulgaris.

More: continued here

Filed under: Clinical Trials on April 2nd, 2008